<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436865</url>
  </required_header>
  <id_info>
    <org_study_id>HM10313</org_study_id>
    <secondary_id>K23HD049454-01A2</secondary_id>
    <nct_id>NCT00436865</nct_id>
  </id_info>
  <brief_title>Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study</brief_title>
  <official_title>Insulin and the Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <brief_summary>
    <textblock>
      The polycystic ovary syndrome is the leading cause of female infertility in the United
      States. The disorder affects approximately 6-10% of women of reproductive age. It is widely
      accepted that &quot;insulin resistance&quot; may be responsible for the infertility of this syndrome.
      Women are insulin resistant when their bodies do not respond to insulin's action to handle
      sugar as they normally should. Because of this insulin resistance, women with the polycystic
      ovary syndrome are also at high risk for developing type 2 diabetes. We have previously shown
      that D-chiro-inositol (DCI), a substance naturally found in our body that helps insulin's
      action, is lacking in women with the polycystic ovary syndrome. Not having enough DCI may
      lead to insulin resistance. The purpose of this study is to determine if weight loss helps to
      replenish the body with DCI and help to promote insulin's action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance is present in women with PCOS. Women with PCOS are at high risk for
      developing type 2 diabetes, presumably due to the insulin resistance that accompanies the
      syndrome. Some actions of insulin may be effected by putative inositolphosphoglycan (IPG)
      mediators of insulin action, and evidence suggests that a deficiency in a specific
      D-chiro-inositol (DCI)-containing IPG may contribute to insulin resistance in individuals
      with impaired glucose tolerance or type 2 diabetes mellitus. A deficiency in DCI may also
      contribute to the insulin resistance in women with PCOS. In PCOS, three separate studies have
      shown that administration of DCI, the precursor to DCI-IPG, to women with PCOS improved
      glucose intolerance while reducing circulating insulin, improved ovulatory function, and
      decreased serum androgens. Serum triglycerides, HDL cholesterol and blood pressure improved
      in some of the studies as well. Collectively, these findings strongly suggest that
      administration of DCI improved insulin sensitivity in women with PCOS, and that a deficiency
      in DCI may contribute to the insulin resistance of this disorder.

      Previous studies of our group demonstrated that women with PCOS, when compared to normal
      women, had a (i) greater than 5-fold increase in the renal clearance of DCI, (ii) 50%
      reduction in the circulating concentration of DCI, and (iii) decreased insulin-stimulated
      release of DCI-IPG during an oral glucose tolerance test (OGTT). Moreover, insulin
      sensitivity (as determined by frequently sampled intravenous glucose tolerance test
      [FSIVGTT]) correlated inversely with renal clearance of DCI. In addition, it appears that
      obesity needs to be present for the abnormality in renal clearance of DCI to be present in
      PCOS, and obesity does not seem to have an effect in DCI renal clearance in normal women.

      Our hypothesis is that obesity modulates the renal clearance of DCI in women with PCOS, but
      not in normal women. A corollary of this hypothesis is that an increased urinary DCI
      clearance leads to a reduction in circulating DCI and insulin-stimulated DCI-IPG release, and
      aggravates insulin resistance in women with PCOS. To test our hypothesis, we propose to study
      the following specific aims:

      Specific Aims:

      Specific Aim 1: Determine if DCI renal clearance in obese women with PCOS is increased
      compared to age- and weight-matched, obese normal women.

      In this aim, we will determine if obese women with PCOS have (i) increased renal clearance of
      DCI, (ii) decreased circulating levels of DCI, and (iii) decreased DCI-IPG release in blood
      during an OGTT, as compared to age- and BMI-matched, obese normal women.

      Specific Aim 2: Determine if weight loss reduces DCI renal clearance in obese women with
      PCOS, but not in age- and weight-matched obese normal women.

      This aim determines if weight loss reverses the abnormalities in DCI handling in PCOS. The
      effects of weight loss on (i) renal clearance of DCI, (ii) circulating levels of DCI, and
      (iii) DCI-IPG release in blood during an OGTT, will be compared between obese women with PCOS
      and age- and BMI-matched obese normal women.

      Specific Aim 3: Determine if a change (reduction) in DCI renal clearance as a result of
      weight loss is correlated with a change (improvement) in insulin sensitivity in obese women
      with PCOS that is independent of weight loss itself.

      In our Preliminary Studies, we have determined that insulin sensitivity has a significant
      inverse relationship with urinary DCI clearance. In this aim, we will determine if decreasing
      DCI renal clearance by weight loss in obese women with PCOS will improve insulin sensitivity
      independent of the degree of weight loss (via statistical adjustment with the degree of
      weight loss as a covariate).

      Specific Aim 4: Determine if an equivalent degree of weight loss in obese women with and
      without PCOS is associated with (i) a greater reduction in DCI renal clearance, and (ii) a
      greater improvement in insulin sensitivity in the PCOS women compared to the normal women.

      To further demonstrate whether improvement in insulin sensitivity as a result of an
      improvement in DCI handling is independent of weight loss itself, women will be stratified by
      the degree of weight loss. For each degree of weight loss, we will determine if obese women
      with PCOS have (i) a greater reduction of renal clearance of DCI and (ii) a greater
      improvement in insulin sensitivity as a result of weight reduction, as compared to
      weight-matched obese normal women.

      If our proposed studies confirm a role for obesity in modulating DCI handling in PCOS, they
      will substantially enhance our understanding of the pathogenesis of PCOS and are likely to
      provide insights into novel treatment strategies directed specifically at the IPG system and
      normalization of its function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Serum D-Chiro-Inositol (DCI) concentrations (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of DCI renal clearance (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of AUC insulin during OGTT (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of bioactive DCI-IPG during OGTT (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of AUC DCI-IPG to AUC insulin during OGTT (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Myo-Inositol (Myo) concentrations (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYO bioactivity (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammatory and cardiovascular markers (Change from baseline to 8 weeks)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>PCOS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PCOS women receiving weight loss intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-PCOS women receiving weight loss intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight loss</intervention_name>
    <arm_group_label>PCOS</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese (â‰¥ 30 kg/m2) premenopausal women with PCOS and normal women between 18-40 years
             of age.

          -  PCOS women only:

               -  oligomenorrhea (&lt;= 8 menstrual periods annually),

               -  biochemical hyperandrogenemia (elevated total or free testosterone),

               -  normal thyroid function tests and serum prolactin, and

               -  exclusion of 21alpha-hydroxylase deficiency by a fasting
                  17alpha-hydroxyprogesterone &lt;200 ng/dl.

          -  Normal women only:

               -  regular monthly menses, and

               -  normal serum total and free testosterone.

          -  All women:

               -  acceptable health on the basis of interview, medical history, physical
                  examination, and laboratory tests (CBC, SMA20, urinalysis),

               -  have not been dieting in the 3 months prior to study enrollment,

               -  signed, witnessed informed consent,

               -  ability to comply with study requirements.

        Exclusion Criteria:

          -  Diabetes mellitus by fasting glucose or OGTT, or clinically significant pulmonary,
             cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant
             disease (other than non-melanoma skin cancer).

          -  Documented or suspected recent (within one year) history of drug abuse or alcoholism.

          -  Ingestion of any investigational drug within 3 months prior to study onset.

          -  Pregnancy as documented by urine hCG.

          -  PCOS women only: Change in PCOS medication regimen (oral contraceptives,
             spironolactone, insulin sensitizers) within 3 months prior to the start of the study.

          -  Normal women only:

               -  history of gestational diabetes,

               -  positive family history for first-degree relative with diabetes,

               -  disorders linked to insulin resistance (hypertension or dyslipidemia),

               -  Use of oral or other systemic contraceptives, or spironolactone within 3 months
                  prior to the start of the study,

               -  Use of medications (including OTC drugs) known to affect insulin sensitivity such
                  as metformin, rosiglitazone, pioglitazone, niacin, corticosteroids, beta
                  blockers, calcium channel blockers and thiazide diuretics within 3 months prior
                  to the start of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai I. Cheang, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University General Clinical Research Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

